替吉奥胶囊单药治疗晚期胃癌的临床观察

摘要

Objective To evaluate the efficacy and toxicities of S-1 capsule for advanced gastric cancer .Methods 87 advanced gastric carcinoma patients with measurable indicators were randomly divided into 2 groups.49 patients in the observation group received S-1 capsule 80 mg/m2 daily in the morning and evening after meal ,14 days was a cycle ,it was repeated with an in-terval of 7 days.The efficacy was evaluated after 2 cycles.38 patients in the control group received capecitabine orally 1500mg each time twice a day,14 days was a cycle,it was repeated with an interval of 7 days,2 and 2 cycles were completed.Efficacy and toxicities were evaluated according to the RECIST 1.1 standard.Results Efficacy of all the patients can be evaluated .Response rate of the observation group and the control group were 48.9%and 42.1%,there had no statistical differences ,but adverse reac-tions and serious reactions of the observation group were significantly less than that of the control group .Conclusion S-1 for ad-vanced gastric cancer is effective ,2with tolerable adverse reactions .It is worthy of further study .%目的：观察替吉奥（ S-1）胶囊单药治疗晚期胃癌的临床疗效及不良反应。方法对87例具有可测量指标的晚期胃癌患者随机分为2组。治疗组49例采用替吉奥胶囊每天80 mg /m2，分早晚2次，餐后口服，1～14天用药，停药7天后重复，2个周期后评价疗效；对照组38例采用卡培他滨1500 mg /次，2次/日，口服，1～14天用药，停药7天后重复，完成2个周期。按RECIST1．1标准评价客观疗效和不良反应。结果87例均可评价疗效；治疗组和对照组的近期有效率（RR）分别为48．9％和42．1％，2组比较差异无统计学意义，但治疗组的不良反应及严重反应发生率明显低于对照组。结论替吉奥单药治疗晚期胃癌的疗效较好，不良反应轻，值得临床进一步研究。